The quest for weight loss has taken a dramatic turn. A wave of new-age solutions, from once-weekly injectables like Wegovy ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Wegovy, to be in pharmacies by the end of June, has been launched in a pen-injection format with strengths ranging from 0.25 ...

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Danish pharma giant Novo Nordisk’s announcement comes months after the launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Novo Nordisk has officially launched its anti-obesity drug Wegovy in India ahead of patent expiry. This move aims to tackle rising obesity rates while facing competition from rival drugs.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...